ProCE Banner Activity

Neoadjuvant Therapy Considerations With CDK4/6 Inhibitors in HR+/HER2- EBC

Slideset Download
Review the latest developments in leveraging CDK4/6 inhibitors in the neoadjuvant setting for patients with HR-positive, HER2-negative early breast cancer.

Released: June 15, 2021

Expiration: June 14, 2022

No longer available for credit.

Share

Faculty

Sara Hurvitz

Sara Hurvitz, MD

Assistant Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Internal Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Sara Hurvitz, MD

Assistant Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Internal Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California